Argon Medical Broadens Oncology Solutions with Asset Acquisition in Microcatheter Technology
Argon Medical Expands its Oncology Product Lineup
Argon Medical, a prominent player in the field of medical devices, has recently announced a significant enhancement to its oncology product offerings through the acquisition of resources linked to the SeQure® and DraKon™ microcatheters. This acquisition was made from Guerbet SA, a well-respected name in medical imaging, and it marks a strategic step forward in Argon Medical's mission to deliver advanced medical solutions in various fields including Interventional Radiology, Vascular Surgery, Interventional Cardiology, and now, Oncology.
The integration of the SeQure and DraKon microcatheters into Argon’s offerings is particularly crucial as it complements their extensive range of biopsy devices which are well-regarded in diagnostic oncology.
What Makes SeQure and DraKon Stand Out?
Microcatheters such as the SeQure and DraKon play an instrumental role in interventional procedures, allowing physicians to introduce therapeutic agents and devices directly into the small vessels supplying blood to tumors. The choice of a microcatheter is often determined by factors such as navigability and compatibility with various therapeutic agents. Both SeQure and DraKon have established themselves as trusted options among healthcare professionals due to their ease of navigation and broad compatibility. Notably, the SeQure microcatheter is recognized as the only reflux control microcatheter that efficiently directs therapeutic agents towards the intended targets by creating a fluid barrier.
Dr. Neal Khurana, a leading expert in the field, emphasized the importance of microcatheters in achieving successful procedures. He expressed that a well-designed microcatheter is pivotal in ensuring optimal navigation and delivery of embolic materials, ultimately leading to better patient outcomes. His endorsement of the DraKon and SeQure technologies highlights their reliability in navigating through challenging vascular paths and efficiently delivering contrast and embolics, even with the smallest catheter sizes.
A Step Towards Enhanced Therapeutic Solutions
According to George Leondis, the President and CEO of Argon Medical, the addition of SeQure and DraKon represents a crucial milestone in their growth strategy. This acquisition not only broadens their product range for oncology professionals but also enhances their capability to improve patient care through cutting-edge medical devices and superior service.
Upon finalizing the acquisition, Argon Medical plans to transition the manufacturing of these microcatheters to their primary facility located in Athens, Texas. The company aims to reintroduce both products to all previous markets while exploring new avenues for distribution across different regions.
About Argon Medical
Founded in 1972, Argon Medical has consistently been at the forefront of innovation in medical products, providing outstanding service and value to professionals in Interventional Radiology, Vascular Surgery, and Interventional Cardiology on a global scale. The company has expanded significantly with over 1,200 employees, operational facilities in various states including Texas, Illinois, New York, and Wisconsin, and an impressive collection of well-known products like the Option™ ELITE IVC Filter, CLEANER™ Rotational Thrombectomy System, and BioPince™ Ultra Full-Core Biopsy Instrument. Their established sales and marketing infrastructure ensures that Argon serves its global clientele effectively, enhancing patient care with innovative solutions.
In summary, Argon Medical’s recent acquisition is a significant move that will not only enhance their oncology product offerings but also help in redefining patient care through sophisticated therapeutic solutions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.